Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

Abstract Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden on the efficacy of ICI + Chemo remains unknown. Methods W...

Full description

Bibliographic Details
Main Authors: Taichi Miyawaki, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cancer Medicine
Subjects:
clinical cancer research
immunology
lung cancer
metastasis
non‐small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.5035

Internet

https://doi.org/10.1002/cam4.5035

Similar Items